The Stanford Institute for Stem Cell Research and Regenerative Medicine Council has published a study on a cancer cell antibodies, can eat the cancer cell signal in practice.
The molecule is a molecule called CD47, which says that cancer can not eat. You have an antibody that CD47 signal that is safe to control how, and how ultimately reduce aid in the fight against cancer is discovered.
The results also show that while CD47 is found in other cells in the body, molecular, anti-CD47 has no influence on them. The link can be the presence of calreticulin, an agent that emits a signal to cancer cells that are attacked with a meal. Stanford Institute Director reports, Dr. Irving Weissman, that although many cancer Calreticulin appears in the cells, not in most normal cell structures. "The research also shows that most do not show the normal cell populations calreticulin and therefore does not stop when the anti-CD47 antibody blocks exposed."
The Institute will continue the impact of calreticulin in the communities to study of cells and how their discovery could help in the fight against cancer.
The molecule is a molecule called CD47, which says that cancer can not eat. You have an antibody that CD47 signal that is safe to control how, and how ultimately reduce aid in the fight against cancer is discovered.
The results also show that while CD47 is found in other cells in the body, molecular, anti-CD47 has no influence on them. The link can be the presence of calreticulin, an agent that emits a signal to cancer cells that are attacked with a meal. Stanford Institute Director reports, Dr. Irving Weissman, that although many cancer Calreticulin appears in the cells, not in most normal cell structures. "The research also shows that most do not show the normal cell populations calreticulin and therefore does not stop when the anti-CD47 antibody blocks exposed."
The Institute will continue the impact of calreticulin in the communities to study of cells and how their discovery could help in the fight against cancer.
No comments:
Post a Comment